2023-12-19

Shanghai Novamab Biology, the world's first inhaled nanobody enterprise, has completed a round B financing of more than 100 million yuan

On December 18,2023, Shanghai Novamab Biopharmaceuticals Co., Ltd. (hereinafter referred to as: "Company or Novamab") successfully completed completed a Series B financing of over 100 million CNY.

More

2023-11-13

The research results of Novamab TROP2-ADC were published in the Journal of Nanobiotechnology!

Recently, Novamab and the team of Professor Zhang Xuyao/Ju Dianwen from the School of Pharmacy, Fudan University, jointly reported that the nanobody-drug conjugate (NDC) molecule targeting TROP2 has p

More

2023-09-26

Novamab Announced Presentation of Encouraging Clinical Data for LQ036 at ATS 2023 International Conference

Novamab Announced Presentation of Encouraging Clinical Data for LQ036 at ATS 2023 International Conference

More

2023-09-18

CDE approves IND application for LQ036 in the treatment of COPD

CDE approves IND application for LQ036 in the treatment of COPD ◇———A global leading Biotech in the  R&D of innovative Nanobody drugs———◇

More

2023-07-04

CEO of Novamab delivered a wonderful speech at the ACCESS CHINA Boston Forum

CEO of Luoqi Biotechnology delivers a speech at the ACCESS CHINA Pharmaceuticals China Boston ForumA leading global enterprise in the research and development of innovative nano antibody drugsThe offl

More

2023-06-28

LQ036 IND application for COPD accepted by CDE

On June 27, 2023, Shanghai Novamab Biological Pharmaceutical Technology Co., Ltd. (hereinafter referred to as "Luoqi Biological") announced that the IND application for COPD indication of LQ036 (LQ036

More

2023-05-25

Novamab presented the latest progress of 3 core assets at the ATS 2023 conference

On May 21, 2023, Dr. Wan Yakun, founder and chairman of Shanghai NovamabBiomedical Technology Co., Ltd., was invited to participate in the 2023 American Thoracic Society International Conference/Annua

More

2023-05-12

Novamab will present the latest progress of its promising products at ATS 2023 and BIO International Convention 2023

A leading global enterprise in the research and development of innovative nano antibody drugsRecently, Dr. Wan Yakun, founder and chairman of Shanghai Novamab Biomedical Technology Co., Ltd., was invi

More

2023-04-06

Novamab:Systematic Opportunities for Antibody Inhalation Administration

In 2022, among the top 20 best-selling drugs in the world, 8 are macromolecular drugs, and the proportion will be higher if COVID-19 is excluded. The two best-selling drugs Humira and Keytruda are ant

More

2023-01-14

洛启生物 祝您元旦快乐

描述为占位文字请客户提供描述为占位文字请客户提供，描述为占位文字请客户提供描述为占位文字请客户提供...

More